(Q38191811)

30 August 2017

1 reference

title

How we manage follicular lymphoma (English)

1 reference

30 August 2017

2

B D Cheson

1 reference

30 August 2017

W Hiddemann

1

1 reference

30 August 2017

publication date

28 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

28

1 reference

30 August 2017

issue

7

1 reference

30 August 2017

page(s)

1388-1395

1 reference

Pathogenesis of follicular lymphoma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

The evolving contribution of hematopoietic progenitor cells to lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Marching single file or 2 abreast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

New agents in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Beyond chemotherapy: new agents for targeted treatment of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Lenalidomide for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.91

Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

12 December 2020

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database

1 reference

12 December 2020

Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy

1 reference

12 December 2020

Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

1 reference

12 December 2020

Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis

1 reference

12 December 2020

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall s

1 reference

12 December 2020

The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin

1 reference

12 December 2020

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

1 reference

12 December 2020

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma

1 reference

12 December 2020

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

12 December 2020

Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

1 reference

12 December 2020

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up

1 reference

12 December 2020

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

Follicular lymphoma and the immune system: from pathogenesis to antibody therapy

1 reference

12 December 2020

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi

1 reference

12 December 2020

Long-term results with radiotherapy for Stage I-II follicular lymphomas

1 reference

12 December 2020

Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy

1 reference

12 December 2020

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

12 December 2020

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

12 December 2020

Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-frühe Stadien

1 reference

12 December 2020

Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University

1 reference

12 December 2020

Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma

1 reference

12 December 2020

Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status

1 reference

12 December 2020

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient

1 reference

12 December 2020

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

12 December 2020

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up

1 reference

12 December 2020

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

1 reference

12 December 2020

Waiting is the hardest part

1 reference

12 December 2020

Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.91

1 reference

Dimensions Publication ID

30 August 2017

1025813325

0 references

1 reference